Comparison of the Vitexagnuscastusovitex and Bromocriptine in the Management of Hyperprolactinemia
DOI:
https://doi.org/10.70749/ijbr.v3i4.3117Keywords:
Hyperprolactinemia, Vitex agnus-castus, Bromocriptine, Prolactin, Amenorrhea, LH, FSH.Abstract
Objective: To study of the effectiveness of vitex agnus-castus and bromocriptine in women with hyperprolactinemic amenorrhea who present themselves. Methodology: It was a randomized controlled trial that was conducted in the Department of Obstetrics and Gynecology of the Lady Willingdon Hospital Lahore. Included were 60 women aged 18 - 35 years who had amenorrhea and had a serum prolactin level > 25 ng/ml. Patients were stratified and equally divided into two groups with a lottery. Group A was fed on Vitex agnus-castus and Group B on bromocriptine. At the baseline and after a month of treatment the levels of serum prolactin, the levels of luteinizing hormone and follicle-stimulating hormone were measured. The SPSS version 25 was used to analyze the data. Any p-value that is less than 0.05 was regarded to be statistically significant. Results: The mean age was 26.43 ± 4.91 years in Group A and 27.16 ± 4.62 years in Group B. Baseline serum prolactin level was 40.18 ± 18.38 ng/ml in the Vitex group and 44.52 ± 15.25 ng/ml in the bromocriptine group. One month of treatment resulted in a large drop in serum prolactin in Group A (23.22 ± 5.91 ng/ml) and Group B (23.36 ± 3.20 ng/ml) and a significant within-group decrease in each group (p < 0.001). But, the difference between the groups after the treatment was statistically irrelevant (p = 0.910). It became possible to normalize prolactin in 70.0 percent patients in the Vitex group and in 76.7 percent patients in bromocriptine group (p = 0.559). Both the LH and FSH levels in the treated two groups were also similar. Conclusion: Both Vitex agnus-castus as well as bromocriptine were effective in decreasing prolactin level in serum after 1 month of treatment. Though slight difference in prolactin normalization rate was observed between bromocriptine and Vitex agnus-castus, this was not significant. Vitex agnus-castus can be viewed as an option in a few patients with mild and moderate hyperprolactinemia.
Downloads
References
1. Kolnikaj, T. S., Musat, M., Salehidoost, R., & Korbonits, M. (2024). Pharmacological causes of hyperprolactinemia. Endotext [Internet].
https://www.ncbi.nlm.nih.gov/books/NBK599196/
2. Puglia, L. T., Lowry, J., & Tamagno, G. (2023). Vitex agnus castus effects on hyperprolactinaemia. Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1269781
3. Höller M, Ramires R, Jäger W, et al. Use of Vitex agnus-castus in patients with menstrual cycle disorders and hyperprolactinemia. Front Pharmacol. 2024;15:1358573. doi:10.3389/fphar.2024.1358573
4. Faron-Górecka, A., Latocha, K., Pabian, P., Kolasa, M., Sobczyk-Krupiarz, I., & Dziedzicka-Wasylewska, M. (2023). The involvement of prolactin in stress-related disorders. International Journal of Environmental Research and Public Health, 20(4), 3257.
https://doi.org/10.3390/ijerph20043257
5. Ahmed E, Khaliq A, Nasrullah S. Comparative study on the effects of bromocriptine and cabergoline in females with hyperprolactinemic amenorrhea. Indo Am J Pharm Sci. 2020;7(10):1025-1029. doi:10.5281/zenodo.4119185.
6. Mehwish, W., Yaseen, S., & Kasi, R. (2020). Compare the Effectiveness of Bromocriptine versus Vitex Agnus Castus Ovitex in Women with Hyperprolactinemia (pp. 1190–1192).
https://pjmhsonline.com/2020/oct_dec/1190.pdf
7. Mendes, C., Fonseca, A. M. D., Alves, M. S., Bayer, L. H. C. M., Veiga, E. C. D. A., Sorpreso, I. C. E., ... & Soares Júnior, J. M. (2022). Narrative review of Vitex agnus-castus in symptoms in Gynecology. Revista da Associação Médica Brasileira, 68, 716-719.
https://doi.org/10.1590/1806-9282.20220174
8. Reinhardt, J. K., Schertler, L., Bussmann, H., Sellner, M., Smiesko, M., Boonen, G., Potterat, O., Hamburger, M., & Butterweck, V. (2024). Vitex agnus castus extract Ze 440: Diterpene and Triterpene’s interactions with dopamine D2 receptor. International Journal of Molecular Sciences, 25(21), 11456.
https://doi.org/10.3390/ijms252111456
9. Ooi, S. L., Watts, S., McClean, R., & Pak, S. C. (2020). Vitex agnus-castus for the treatment of cyclic Mastalgia: A systematic review and meta-analysis. Journal of Women's Health, 29(2), 262-278.
https://doi.org/10.1089/jwh.2019.7770
10. Das, N., Salgueiro, A. C., Choudhury, D. R., Mandal, S. K., Logesh, R., Hassan, M. M., & Devkota, H. P. (2021). Traditional uses, phytochemistry, and pharmacology of genus Vitex (Lamiaceae). Phytotherapy Research, 36(2), 571-671.
https://doi.org/10.1002/ptr.7330
11. Glezer, A., Garmes, H. M., Kasuki, L., Martins, M., Elias, P. C., Nogueira, V. D., Rosa-e-Silva, A. C., Maciel, G. A., Benetti-Pinto, C. L., & Nácul, A. P. (2024). Diagnosis of hyperprolactinemia in women: A position statement from the Brazilian Federation of gynecology and obstetrics associations (Febrasgo) and the Brazilian society of endocrinology and metabolism (SBEM). Archives of Endocrinology and Metabolism, 68.
https://doi.org/10.20945/2359-4292-2023-0502
12. Benetti-Pinto, C. L., Nácul, A. P., Rosa-e-Silva, A. C., Maciel, G. A., Nogueira, V. D., Elias, P. C., Martins, M., Kasuki, L., Garmes, H. M., & Glezer, A. (2024). Treatment of hyperprolactinemia in women: A position statement from the Brazilian Federation of gynecology and obstetrics associations (Febrasgo) and the Brazilian society of endocrinology and metabolism (SBEM). Archives of Endocrinology and Metabolism, 68.
https://doi.org/10.20945/2359-4292-2023-0504
13. Petersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., Greenman, Y., Gurnell, M., Ho, K. K., Honegger, J., Ioachimescu, A. G., Kaiser, U. B., Karavitaki, N., Katznelson, L., Lodish, M., … Melmed, S. (2023). Diagnosis and management of prolactin-secreting pituitary adenomas: A pituitary society international consensus statement. Nature Reviews Endocrinology, 19(12), 722-740.
https://doi.org/10.1038/s41574-023-00886-5
14. Auriemma, R. S., Pirchio, R., Pivonello, C., Garifalos, F., Colao, A., & Pivonello, R. (2023). Approach to the patient with Prolactinoma. The Journal of Clinical Endocrinology & Metabolism, 108(9), 2400-2423.
https://doi.org/10.1210/clinem/dgad174
15. Puglia, L. T., Lowry, J., & Tamagno, G. (2023). Vitex agnus castus effects on hyperprolactinaemia. Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1269781
16. Höller, M., Steindl, H., Abramov-Sommariva, D., Kleemann, J., Loleit, A., Abels, C., & Stute, P. (2024). Use of Vitex agnus-castus in patients with menstrual cycle disorders: A single-center retrospective longitudinal cohort study. Archives of Gynecology and Obstetrics, 309(5), 2089-2098.
https://doi.org/10.1007/s00404-023-07363-4
17. Sirotkin, A. V. (2025). Effects, mechanisms of action and application of Vitex agnus-castus for improvement of health and female reproduction. Phytotherapy Research, 39(3), 1484-1493.
https://doi.org/10.1002/ptr.8438
18. Maiter, D. (2022). Mild hyperprolactinemia in a couple: What impact on fertility? Annales d'Endocrinologie, 83(3), 164-167.
https://doi.org/10.1016/j.ando.2022.04.002
19. Fachi, M. M., Deus Bueno, L., Oliveira, D. C., Silva, L. L., & Bonetti, A. F. (2021). Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta‐analysis. Journal of Clinical Pharmacy and Therapeutics, 46(6), 1549-1556.
https://doi.org/10.1111/jcpt.13460
20. Ma, K., Ma, L., Huang, T., Wang, Y., Zhong, G., Gao, C., Zhou, Z., & Luo, J. (2024). The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: A systematic review and network meta-analysis. Expert Opinion on Drug Safety, 24(7), 773-786.
https://doi.org/10.1080/14740338.2024.2416918
21. Zhang, C. D., & Ioachimescu, A. G. (2024). Prolactinomas: preconception and during pregnancy. Endocrinology and Metabolism Clinics of North America, 53(3), 409–419.
https://doi.org/10.1016/j.ecl.2024.05.004
22. Santos, A. C., Yela, D. A., Nakamura, R. M., Ribas, B. C., Silva, P. H. R. e, Mota, B., & Benetti-Pinto, C. L. (2024). Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes? Revista Da Associação Médica Brasileira, 70(10).
https://doi.org/10.1590/1806-9282.20240634
23. Alidrisi, H. A., Alobaidy, H. F., Reman, K. A., Alzujajy, Q. B., Hussein, I. H., & Mansour, A. A. (2025). Management outcomes of prolactinoma: a retrospective study from Southern Iraq. Journal of Medicine and Life, 18(9), 869–877.
https://doi.org/10.25122/jml-2025-0050
24. Mele, C., Zavattaro, M., Pitino, R., Romanisio, M., Ferrero, A., Sturnia, S., Catenazzi, S., Rosmini, F., Baldi, S., Marzullo, P., Aimaretti, G., Prodam, F., & Caputo, M. (2025). Prolactin secreting pituitary neuroendocrine tumors treated by dopamine agonists: Predictors of response. Frontiers in Endocrinology, 16.
https://doi.org/10.3389/fendo.2025.1664621
25. Reman, K. A., Alidrisi, H. A., Alhamza, A. H., Alobaidy, H. F., & Mansour, A. A. (2025). Cystic versus non-cystic prolactinoma: Clinical, hormonal, radiological, and remission outcomes in Basrah. Frontiers in Endocrinology, 16.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
